Tech Company Financing Transactions
QurAlis Funding Round
On 3/9/2023, QurAlis secured $88 million in Series B investment from ALS Investment Fund, Amgen Ventures and Dementia Discovery Fund.
Transaction Overview
Company Name
Announced On
3/9/2023
Transaction Type
Venture Equity
Amount
$88,000,000
Round
Series B
Investors
Dementia Discovery Fund (Jonathan Behr)
INKEF Capital (Roel Bulthuis)
Proceeds Purpose
The company intends to use the funds to advance clinical development of QRL-201 and QRL-101, its lead product candidates in ALS, support ongoing and planned research, as well as the advancement of its pipeline with therapeutic candidates that target specific components of ALS and genetically related frontotemporal dementia (FTD) pathology and defined ALS patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St. North
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
QurAlis is specifically focused on discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Jonathan Fleming
Chief Executive Officer
Kasper Roet
Chief Scientific Officer
Daniel Elbaum
Founder
Kevin Eggan
Founder
Clifford Woolf
Browse more venture capital transactions:
Prev: 3/9/2023: MentorcliQ venture capital transaction
Next: 3/9/2023: Cado Security venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs